Tysabri Seen to Improve Cognition in RRMS Patients Over 2 Years in Retrospective Study
SEPTEMBER 6, 2018 BY MARTA FIGUEIREDO Tysabri (natalizumab) was reported in a small retrospective study to significantly improve cognitive abilities in people…
Smoking Increases Relapse Rate in RRMS Patients on Tysabri, Study Suggests
August 7, 2018 Smoking increases the relapse rate in patients with relapsing-remitting multiple sclerosis being treated with Tysabri , an…
Stuart Schlossman
Natalizumab May Reduce Disease Progression in Multiple Sclerosis
For patients with secondary progressive multiple sclerosis, natalizumab was not superior to placebo for reducing disability progression, according to results published…
Stuart Schlossman
Tysabri-associated Progressive Multifocal Leukoencephalopathy (PML)
Discussed by Aaron Boster, MD What is PML, what causes it, and the risk factors for infection associated with taking…
Stuart Schlossman
Cognitive functioning following one-year Natalizumab treatment: A non-randomized clinical trial.
Rorsman I, et al. Acta Neurol Scand. 2017. Show full citation Abstract OBJECTIVES: Cognitive impairment is common in multiple sclerosis (MS)…
Stuart Schlossman
Evaluation of pregnancy outcomes from the Tysabri® (natalizumab) pregnancy exposure registry: a global, observational, follow-up study.
…
Stuart Schlossman
Natalizumab in Multiple Sclerosis: Long-Term Management
…
Stuart Schlossman
Lack of natalizumab concentration increase before PML argues against extending dosing interval
…
Stuart Schlossman
MS Relapses During Natalizumab Therapy Traced to Drug’s Greater Impact on Regulatory T-cells
…
Stuart Schlossman
Tysabri’s Success in Impairing the Immune System in RRMS May Be Source of Its Problems
…
Stuart Schlossman
